Piperacillin/tazobactam versus cefepime or carbapenems for cefoxitin-non-susceptibleEnterobacter cloacae,Klebsiella aerogenes,Citrobacter freundii,Serratia marcescensandMorganella morganiibacteraemia in immunocompromised patients

This is the authors' abstract. We don't add key points for this paper.

In immunocompromised patients with bacteraemia due to cefoxitin-non-susceptible Enterobacterales, definitive treatment with piperacillin/tazobactam was associated with an increased risk of microbiological failure and higher odds of clinical or microbiological failure compared with cefepime or carbapenems.